SBMU Journals
  • New Submission
  • Register
  • Login
  • English
    • 简体中文

Archives of Academic Emergency Medicine

  • Home
  • About
    • Policies
    • Editorial Team
    • Reviewer guideline
    • Contact
  • Issues
    • Current
    • Archives
  • Announcements
  • Indexing/Abstracting
  • For authors
    • New Submission
    • Author guidelines
    • Article withdrawal
    • Peer review process
    • FAQ
  • Ethics
    • Ethical requirements
    • Plagiarism Policy
    • Authorship conflicts
    • Malpractice statements
    • Copyright Notice
    • Intellectual properties
    • Preprint Policy
    • Privacy Statement
    • Artificial intelligence & Authorship
    • Retraction Cosiderations
Advanced Search
  1. Home
  2. Archives
  3. Vol. 8 No. 1 (2020): Continuous volume
  4. Letter

Vol. 8 No. 1 (2020)

January 2020

Superinfection by Trichomonas, a Second Reason to Add Metronidazole to COVID-19 Treatment; a Letter to Editor

  • Christophe Duboucher

Archives of Academic Emergency Medicine, Vol. 8 No. 1 (2020), 1 January 2020 , Page e83
https://doi.org/10.22037/aaem.v8i1.971 Published: 2020-10-22

  • View Article
  • Download
  • Cite
  • References
  • Statastics
  • Share

Abstract

Dear Editor,

All countries are struggling against the COVID-19 pandemic. One million deaths have been recorded. Acute respiratory distress syndrome (ARDS) is the major complication. No antiviral therapy has been shown to be clearly effective for reducing the rate of mortality in published randomised controlled trials.

In an article published in the last issue of Archives of Academic Emergency Medicine, metronidazole is suggested to be tested in clinical trials (1). In vitro and in vivo studies have revealed that metronidazole could decrease the levels of several cytokines. It could also decrease neutrophil-generated reactive oxygen species, and thus could counteract majority of the immunopathological manifestations of the COVID-19 infection.

Metronidazole could be included in clinical trials for another reason. More than ten years ago we observed that lungs of patients diseased from ARDS, show superimposed infection by trichomonads (2).

Keywords:
  • COVID-19, metronidazole, Respiratory Distress Syndrome, SARS-CoV-2, trichomonas infections
  • pdf

How to Cite

1.
Duboucher C. Superinfection by Trichomonas, a Second Reason to Add Metronidazole to COVID-19 Treatment; a Letter to Editor. Arch Acad Emerg Med [Internet]. 2020 Oct. 22 [cited 2026 Jul. 7];8(1):e83. Available from: https://journals.sbmu.ac.ir/aaem/index.php/AAEM/article/view/971
  • ACM
  • ACS
  • APA
  • ABNT
  • Chicago
  • Harvard
  • IEEE
  • MLA
  • Turabian
  • Vancouver
  • Endnote/Zotero/Mendeley (RIS)
  • BibTeX

References

Gharebaghi R, Heidary F, Moradi M, Parvizi M. Metronidazole; a potential novel addition to the COVID-19 treatment regimen. Archives of Academic Emergency Medicine. 2020;8(1).

Duboucher C, Barbier C, Beltramini A, Rona M, Ricome J-L, Morel G, et al. Pulmonary superinfection by trichomonads in the course of acute respiratory distress syndrome. Lung. 2007;185(5):295-301.

Duboucher C, Caby S, Pierce RJ, Capron M, DEI‐CAS E, Viscogliosi E. Trichomonads as superinfecting agents in Pneumocystis pneumonia and acute respiratory distress syndrome. Journal of Eukaryotic Microbiology. 2006;53:S95-S7.

Duboucher C, Gerbod D, Noël C, Durand-Joly I, Delgado-Viscogliosi P, Leclerc C, et al. Frequency of trichomonads as coinfecting agents in Pneumocystis pneumonia. Acta cytologica. 2005;49(3):273-7.

Jacobs JA, Dieleman MM, Cornelissen E, Groen E, Wagenaar SS, Drent M. Bronchoalveolar lavage fluid cytology in patients with Pneumocystis carinii pneumonia. Acta cytologica. 2001;45(3):317.

  • Abstract Viewed: 364 times
  • pdf Downloaded: 194 times

Download Statastics

  • Linkedin
  • Twitter
  • Facebook
  • Google Plus
  • Telegram

Make a Submission

Make a Submission

SJR

SCImago Journal & Country Rank

COPE

Current Issue

  • Atom logo
  • RSS2 logo
  • RSS1 logo

Information

  • For Readers
  • For Authors
  • For Librarians
  • Home
  • Archives
  • Submissions
  • About the Journal
  • Editorial Team
  • Contact

This journal is distributed under the terms of CC BY-NC 3.0. Design and publishing by SBMU journals. All credits and honors to PKP for their OJS. 

 Sitemap | ISSN-ONLINE: 2645-4904

Support Contact: ma.saghaei63@gmail.com

With the goal of net zero carbon emissions, this journal is published only in electronic format.

Powered by OJSPlus